ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/TIGIT
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/TIGIT
18
trial(s) found.
NCT07720284
Curative
Phase 3
Recruiting
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (
TU-04
)
anti-Trop2 antibody-drug conjugate
bispecific PD-1/TIGIT antibody
Urothelial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT07431281
Advanced
Phase 3
Recruiting
A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02) (
D9803C00001
)
anti-CLDN18.2 antibody-drug conjugate
bispecific PD-1/TIGIT antibody
fluoropyrimidine
Gastric cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07221253
Advanced
Phase 3
Recruiting
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02) (
AB02
)
anti-PD-L1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Biliary tract cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07115043
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors (
D7350C00001
)
CD8-guided IL-2 candidate
+ bispecific PD-1/TIGIT antibody
Gastric cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT07098338
Advanced
Phase 2
Recruiting
An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (
LIBRA
)
Datopotamab Deruxtecan
Ramucirumab
Rilvegostomig
anti-Trop2 antibody-drug conjugate
anti-VEGFR2 monoclonal antibody
bispecific PD-1/TIGIT antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,TIGIT-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGFR2-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGFR2-targeting
therapeutic modality,bispecific antibody
+ bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06989112
Advanced
Phase 3
Recruiting
DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer (
DE-01
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Endometrial cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06921785
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (
ARTEMIDE-HCC01
)
anti-CTLA4 monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/TIGIT antibody
Hepatocellular carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NA
NA
NCT06868277
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04) (
ARTEMIDELung04
)
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06764875
Advanced
Phase 3
Recruiting
A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) (
D702AC00001
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Gastric cancer
Gastroesophageal junction adenocarcinoma
HER2-positive gastric cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06692738
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02) (
D702BC00001
)
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
NCT06627647
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03) (
D702FC00001
)
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
NCT06467357
Advanced
Phase 3
Recruiting
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (
DESTINY-BTC01
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-PD-L1 monoclonal antibody
antimetabolite
bispecific PD-1/TIGIT antibody
platinum-based antineoplastic agent
Biliary tract cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06357533
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (
TROPION-Lung10
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
bispecific PD-1/TIGIT antibody
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
NCT06003621
Advanced
Phase 2
Recruiting
A Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients With Advanced Solid Tumours. (
MoST-TAP
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
NOT Non-small cell lung cancer
Solid tumour
NSW
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2640 - Albury - Border Medical Oncology Research Unit
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4350 - Toowoomba - Toowoomba Hospital
4700 - Rockhampton - Rockhampton Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
4870 - Cairns - Cairns Base Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05123482
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR) (
D6900C00001
)
anti-B7H4 antibody-drug conjugate
+ bispecific PD-1/TIGIT antibody
Squamous non-small-cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04929223
Advanced
Phase 1
Recruiting
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (
WO42758
)
Atezolizumab
Bevacizumab
CDK7 inhibitor
Cetuximab
Divarasib
Inavolisib
KRAS G12C inhibitor
KRAS G12C inhibitor,OFF-state inhibitor
KRAS inhibitor
KRAS inhibitor,mutant selective
PI3K alpha inhibitor
SY-5609
Tiragolumab
anti-EGFR monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
cancer therapy
cancer therapy,CDK7-targeting
cancer therapy,EGFR-targeting
cancer therapy,KRAS-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,EGFR-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ anti-TIGIT monoclonal antibody
Colorectal adenocarcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04686305
Advanced
Phase 1
Recruiting
A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03) (
DL03
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
+ bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
Amezalpat
Atezolizumab
Bevacizumab
HIF2a inhibitor
Imdatifan
Muzastotug
PPAR-alpha inhibitor
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ anti-TIGIT monoclonal antibody
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (18)
Recruitment Country and State
VIC (14)
NSW (11)
QLD (9)
WA (9)
SA (3)
TAS (2)
ACT (1)
NZ (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (3)
Phase 2 (2)
Phase 3 (11)
Trial Type
Advanced (17)
Curative (1)
Cancer Therapy Class
PD-1/PD-L1
100%
TIGIT
100%
PD-1
89%
PD-L1
44%
ERBB2
22%
Trop2
17%
CTLA4
17%
VEGF
17%
Nectin4
6%
CLDN18.2
6%
VEGFR2
6%
B7H4
6%
PARP
6%
PARP1-selective
6%
CDK7
6%
EGFR
6%
KRAS
6%
PI3Kalpha
6%
HIF2a
6%
IL-6
6%
LAG3
6%
PPAR-alpha
6%
Facility
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (6)
3168 - Clayton - Monash Medical Centre (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
6150 - Murdoch - Fiona Stanley Hospital (4)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
3002 - East Melbourne - Epworth Freemasons (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
7000 - Hobart - Royal Hobart Hospital (2)
2500 - Wollongong - Wollongong Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
4812 - Hyde Park - Icon Cancer Centre Townsville (2)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
2605 - Garran - The Canberra Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
NA
4102 - Woolloongabba - Princess Alexandra Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
4350 - Toowoomba - Toowoomba Hospital (1)
4700 - Rockhampton - Rockhampton Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
4870 - Cairns - Cairns Base Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Gastrointestinal cancer
Upper gastrointestinal cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Hepatobiliary cancer
Gastric cancer
Gastroesophageal cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Biliary tract cancer
Pancreatobiliary cancer
Hepatocellular carcinoma
Urogenital cancer
Urothelial carcinoma
Endometrial cancer
Gynaecological cancer
Gastric adenocarcinoma
HER2-positive gastric cancer
Non-squamous non-small-cell lung cancer
Squamous non-small-cell lung cancer
Colorectal adenocarcinoma
Colorectal cancer
Lower gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy